Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Alnylam to Webcast Presentation at the Annual BIO Investor Forum on October 19, 2005.


CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals Alnylam Pharmaceuticals Inc. (NYSE: ALNY), a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the annual BIO Investor Forum on Wednesday, October 19, 2005, at 3:40 p.m. PDT PDT
abbr.
Pacific Daylight Time


PDT Pacific Daylight Time

PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del PacĂ­fico

PDT 
, at the Palace Hotel in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden .

A live audio webcast of this presentation will be available on the "Investors" section of the company's website, http://www.alnylam.com. A replay of the presentation will be posted on the Alnylam website approximately three hours after the event, and will be archived for 30 days.

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference RNA interference
n.
A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes.
, or RNAi. The company, founded in 2002 by scientific pioneers in the field of RNAi, maintains a leadership position in fundamental patents, technology, and know-how relating to RNAi. Alnylam is applying its expertise in RNAi to address multiple therapeutic opportunities that cannot effectively be addressed with small molecules or antibodies, the two current major classes of drugs. The company's expertise in designing and optimizing RNAi therapeutics has enabled Alnylam to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company's global headquarters are in Cambridge, Massachusetts, with an additional operating unit operating unit

A type of operating company that engages in transactions with outsiders and that is owned by another business. For example, in 1995 the stockholders of Capital Cities/ABC approved a $19 billion merger with the Walt Disney Company, whereupon
 in Kulmbach, Germany. For more information, please visit www.alnylam.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 13, 2005
Words:217
Previous Article:Wong Joins United American Bank; Community Bank Eyes South Bay Commercial Lending Market.
Next Article:CEA Wins Technology and Engineering Emmy Award; Standardization of Closed Captioning Technology Recognized for Innovation and Impact.
Topics:



Related Articles
AVANT To Present At 2005 BIO Investor Forum.
Seattle Genetics to Present at Two Upcoming Investor Conferences.
Insmed to Present at the BIO Investor Forum Conference.
Alnylam to Webcast Presentation at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005.
Alnylam to Webcast its R&D Day on Wednesday, December 14, 2005.
Alnylam to Webcast Presentation at the 24th Annual JPMorgan Healthcare Conference on January 11, 2006.
Alnylam to Host Conference Call to Discuss Collaboration with Novartis to Develop RNAi Therapeutics for Pandemic Flu.
Alnylam to Host Conference Call To Discuss Biogen Idec Collaboration.
Alnylam to Webcast Presentation at the BIO InvestorForum 2006.
Alnylam to Webcast Presentation and Panel Discussion at the 9th Annual BIO CEO & Investor Conference.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles